Vir Biotechnology, Inc. VIR Restructuring Costs And Asset Impairment Charges
Restructuring Costs And Asset Impairment Charges at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCostsAndAssetImpairmentCharges.
The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vir Biotechnology, Inc.'s restructuring costs and asset impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vir Biotechnology, Inc.'s restructuring costs and asset impairment charges?
- Vir Biotechnology, Inc. (VIR) reported restructuring costs and asset impairment charges of $0 in Q1 2026.
- How has Vir Biotechnology, Inc.'s restructuring costs and asset impairment charges changed year-over-year?
- Vir Biotechnology, Inc.'s restructuring costs and asset impairment charges increased by 100.0% year-over-year, from -$10K to $0.
- What does restructuring costs and asset impairment charges mean?
- This metric represents non-recurring expenses related to organizational restructuring, workforce reductions, or the write-down of long-lived assets due to impairment. It provides insight into management's efforts to streamline operations or adjust to changing business conditions by shedding underperforming assets. Investors monitor this to distinguish between core operational spending and one-time charges that impact short-term profitability.